AbSci Corporation (ABSI) Actualités

Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day

Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development...

Form 4 - Statement of changes in beneficial ownership of securities

Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a...

Form 8-K - Current report

Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Absci to Host R&D Day on December 12, 2024

VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a...

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation...

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a...

Form 4 - Statement of changes in beneficial ownership of securities